Crizotinib is a multikinase inhibitor (MKI) with activity against ROS1, ALK, and mesenchymal-epidermal transition (MET).4,37 The FDA approval of crizotinib for the treatment of patients with advanced ROS1+ NSCLC was based on the results from a multicenter phase I trial PROFILE 1001, which demonstrated an objective response rate (ORR) of 72% and median progression-free survival (mPFS) of 19.2 months in this patient population.4,21 The most frequent adverse events (AEs) include visual impairment, nausea, vomiting, diarrhea, constipation, edema, and elevated aminotransferase levels. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.